Refine
Year of publication
Document Type
- Article (193)
- Preprint (141)
- Conference Proceeding (1)
Has Fulltext
- yes (335)
Is part of the Bibliography
- no (335)
Keywords
- BESIII (16)
- Branching fraction (12)
- e +-e − Experiments (10)
- Particle and Resonance Production (5)
- Charm Physics (4)
- Charmonium (4)
- Hadronic decays (4)
- Lepton colliders (4)
- Quarkonium (4)
- Branching fractions (3)
Institute
- Physik (303)
- Medizin (16)
- Geowissenschaften (5)
- Frankfurt Institute for Advanced Studies (FIAS) (3)
- Informatik (3)
- Zentrum für Arzneimittelforschung, Entwicklung und Sicherheit (ZAFES) (3)
- Biochemie und Chemie (2)
- Biodiversität und Klima Forschungszentrum (BiK-F) (2)
- Biowissenschaften (2)
- Psychologie (2)
- Senckenbergische Naturforschende Gesellschaft (2)
- Biochemie, Chemie und Pharmazie (1)
- Extern (1)
- Institut für Ökologie, Evolution und Diversität (1)
- Pharmazie (1)
- Wirtschaftswissenschaften (1)
Interleukin (IL)-22 is a STAT3-activating cytokine displaying characteristic AU-rich elements (ARE) in the 3'-untranslated region (3'-UTR) of its mRNA. This architecture suggests gene regulation by modulation of mRNA stability. Since related cytokines undergo post-transcriptional regulation by ARE-binding tristetraprolin (TTP), the role of this destabilizing protein in IL-22 production was investigated. Herein, we demonstrate that TTP-deficient mice display augmented serum IL-22. Likewise, IL-22 mRNA was enhanced in TTP-deficient splenocytes and isolated primary T cells. A pivotal role for TTP is underscored by an extended IL-22 mRNA half-life detectable in TTP-deficient T cells. Luciferase-reporter assays performed in human Jurkat T cells proved the destabilizing potential of the human IL-22-3'-UTR. Furthermore, overexpression of TTP in HEK293 cells substantially decreased luciferase activity directed by the IL-22-3'-UTR. Transcript destabilization by TTP was nullified upon cellular activation by TPA/A23187, an effect dependent on MEK1/2 activity. Accordingly, IL-22 mRNA half-life as determined in TPA/A23187-stimulated Jurkat T cells decreased under the influence of the MEK1/2 inhibitor U0126. Altogether, data indicate that TTP directly controls IL-22 production, a process counteracted by MEK1/2. The TTP-dependent regulatory pathway described herein likely contributes to the role of IL-22 in inflammation and cancer and may evolve as novel target for pharmacological IL-22 modulation.